全文获取类型
收费全文 | 1010篇 |
免费 | 38篇 |
国内免费 | 78篇 |
专业分类
耳鼻咽喉 | 2篇 |
儿科学 | 42篇 |
妇产科学 | 16篇 |
基础医学 | 98篇 |
口腔科学 | 15篇 |
临床医学 | 145篇 |
内科学 | 191篇 |
皮肤病学 | 22篇 |
神经病学 | 26篇 |
特种医学 | 363篇 |
外科学 | 32篇 |
综合类 | 21篇 |
预防医学 | 25篇 |
眼科学 | 1篇 |
药学 | 78篇 |
肿瘤学 | 49篇 |
出版年
2023年 | 3篇 |
2021年 | 3篇 |
2020年 | 2篇 |
2019年 | 1篇 |
2018年 | 10篇 |
2017年 | 7篇 |
2016年 | 9篇 |
2015年 | 9篇 |
2014年 | 15篇 |
2013年 | 17篇 |
2012年 | 23篇 |
2011年 | 11篇 |
2010年 | 26篇 |
2009年 | 40篇 |
2008年 | 22篇 |
2007年 | 80篇 |
2006年 | 19篇 |
2005年 | 23篇 |
2004年 | 12篇 |
2003年 | 21篇 |
2002年 | 13篇 |
2001年 | 19篇 |
2000年 | 17篇 |
1999年 | 21篇 |
1998年 | 67篇 |
1997年 | 74篇 |
1996年 | 51篇 |
1995年 | 69篇 |
1994年 | 37篇 |
1993年 | 37篇 |
1992年 | 18篇 |
1991年 | 20篇 |
1990年 | 17篇 |
1989年 | 37篇 |
1988年 | 36篇 |
1987年 | 23篇 |
1986年 | 28篇 |
1985年 | 47篇 |
1984年 | 18篇 |
1983年 | 12篇 |
1982年 | 25篇 |
1981年 | 14篇 |
1980年 | 24篇 |
1979年 | 4篇 |
1978年 | 4篇 |
1977年 | 15篇 |
1976年 | 15篇 |
1975年 | 9篇 |
1970年 | 1篇 |
1906年 | 1篇 |
排序方式: 共有1126条查询结果,搜索用时 15 毫秒
61.
62.
Repeated injections of 131I-rituximab show patient-specific stable biodistribution and tissue kinetics 总被引:1,自引:0,他引:1
Antonescu C Bischof Delaloye A Kosinski M Monnin P Schaffland AO Ketterer N Grannavel C Kovacsovics T Verdun FR Buchegger F 《European journal of nuclear medicine and molecular imaging》2005,32(8):943-951
Purpose It is generally assumed that the biodistribution and pharmacokinetics of radiolabelled antibodies remain similar between dosimetric and therapeutic injections in radioimmunotherapy. However, circulation half-lives of unlabelled rituximab have been reported to increase progressively after the weekly injections of standard therapy doses. The aim of this study was to evaluate the evolution of the pharmacokinetics of repeated 131I-rituximab injections during treatment with unlabelled rituximab in patients with non-Hodgkins lymphoma (NHL).Methods Patients received standard weekly therapy with rituximab (375 mg/m2) for 4 weeks and a fifth injection at 7 or 8 weeks. Each patient had three additional injections of 185 MBq 131I-rituximab in either treatment weeks 1, 3 and 7 (two patients) or weeks 2, 4 and 8 (two patients). The 12 radiolabelled antibody injections were followed by three whole-body (WB) scintigraphic studies during 1 week and blood sampling on the same occasions. Additional WB scans were performed after 2 and 4 weeks post 131I-rituximab injection prior to the second and third injections, respectively.Results A single exponential radioactivity decrease for WB, liver, spleen, kidneys and heart was observed. Biodistribution and half-lives were patient specific, and without significant change after the second or third injection compared with the first one. Blood T1/2, calculated from the sequential blood samples and fitted to a bi-exponential curve, was similar to the T1/2 of heart and liver but shorter than that of WB and kidneys. Effective radiation dose calculated from attenuation-corrected WB scans and blood using Mirdose3.1 was 0.53+0.05 mSv/MBq (range 0.48–0.59 mSv/MBq). Radiation dose was highest for spleen and kidneys, followed by heart and liver.Conclusion These results show that the biodistribution and tissue kinetics of 131I-rituximab, while specific to each patient, remained constant during unlabelled antibody therapy. RIT radiation doses can therefore be reliably extrapolated from a preceding dosimetry study. 相似文献
63.
Tu'meh SS; Tracy DA; Wynne J; Konstam MA; Kozlowski JF; Neumann AL; Holman BL 《Radiology》1982,145(2):463-466
The authors describe a simple technique for diagnosis of tricuspid regurgitation. Red blood cells were labeled in vivo with 99mTc and 22 patients were studied with ECG-gated blood-pool imaging of the liver. A single region of interest was manually drawn around the liver and a time-activity curve obtained. The per cent change in liver counts during the cardiac cycle was found to be significantly higher in the 12 patients with tricuspid regurgitation (Group I) (mean, 4.04 +/- 1.6%; range, 1.3-21.4%) compared with the 10 controls (Group II) (mean, 0.35 +/- 0.16%; range, 0.013-1.3%) (p less than 0.05). Using a 1% change in liver counts as the criterion of a positive study, all 12 cases in Group I were diagnosed correctly, but there was one false positive in Group II; thus the sensitivity was 100% and the specificity 90%. 相似文献
64.
Postembolic colonic infarction 总被引:12,自引:0,他引:12
65.
Schaffland AO Delaloye AB Kosinski M Dupertuis YM Buchegger F 《Nuclear medicine communications》2004,25(5):461-468
BACKGROUND AND METHODS: 5-Iodo-2'-deoxyuridine (IdUrd) radiolabelled with the positron emitter I or with the gamma and Auger electron emitters I or I has been proposed for cancer diagnosis and therapy. We modified the synthesis to reliably obtain [I]IdUrd and [I]IdUrd by using an Iodogen supported destannylation reaction of 5-(tri-n-butylstannyl)-2'-deoxyuridine (Bu3SndUrd) which meets the requirements for good laboratory practice (GLP) and good clinical practice (GCP). A method of purification was developed to eliminate by-products as well as any unreacted starting material. RESULTS: [I]IdUrd, which originated from a trace of iodide in the Bu3SndUrd precursor, was identified as the unknown by-product reported for this method. This trace could be eliminated by modified purification of Bu3SndUrd. Stabilization of pH was essential for unequivocal identification of radiolabelled IdUrd and possible degradation products in the different systems tested for quality control. Biodistribution in tumour bearing nude mice was measured as early as 3 and 6 h after i.v. injection of [I]IdUrd. This compound showed high and specific activity uptake in tumour and dividing tissues when combined with 5-fluoro-2'-deoxyuridine pre-treatment. Uptake was specifically inhibited by injection of excess thymidine. 相似文献
66.
Radioimmunotherapy (RIT) represents an exciting new therapeutic option for the treatment of B-cell non-Hodgkin's lymphoma (NHL), emerging at a time when significant advances have been made in NHL classification, molecular genetics and treatment. Despite recent treatment advances, including the use of fludarabine phosphate-based combination chemotherapies, able to eradicate minimal residual disease, there remains much room for improvement. The incorporation of RIT into treatment schedules is an attractive option to exploit the extreme sensitivity of lymphoma cells to irradiation. In this supplement, we examine the potential future roles for RIT in the light of past and present therapies, existing RIT clinical data and the unique attributes of radiolabeled monoclonal antibodies. 相似文献
67.
68.
银杏叶制剂对心绞痛患者的抗氧化和抗脂质过氧化作用 总被引:15,自引:0,他引:15
目的:探讨银杏叶制剂对心绞痛患者的抗氧化和抗脂质过氧化作用。方法:检测了78例心绞痛患者经银杏叶制剂“天宝宁”治疗前后的血浆维生素C(P-VC)、维生素E(P-VE)、β-胡萝卜素(P-β-CAR)、过氧化脂质(P-LPO)以及红细胞超氧化物歧化酶(E-SOD)、过氧化氢酶(E-CAT)、谷胱甘肽过氧化物酶(E-GSH-PX)、过氧化脂质(E-LPO)值。结果:与治疗前比较,治疗后的P-VC、P- 相似文献
69.
控制和影响神经干细胞增殖分化为神经元细胞的途径及因素 总被引:1,自引:1,他引:1
目的:探讨控制和影响神经干细胞向神经元细胞转化途径的因素。资料来源:应用计算机检索Medline和cnki数据库1990-01/2006-06期间的有关神经干细胞和增殖与分化关系的文献,检索词“NSC,proliferation,differentiation”,并限定文章语言种类为English。同时计算机检索中国生物医学文献数据库1990-01/2006-06期间的相关文献,限定文章语言种类为中文,检索词“神经干细胞、增殖、分化”。资料选择:选取关于影响神经干细胞增殖与分化特别是机制方面的相关文献,删除未进行对照的试验研究的文章,然后查余下的文献全文,进一步判断是否采用对照。纳入标准:平行对照组,即未采用影响神经干细胞增殖与分化的因素或正常对照;实验组为采用干扰神经干细胞增殖与分化的因素。排除明显不随机的试验。质量评价主要考察资料的真实性,调查设计是否严密,实施过程是否严格,统计学处理是否合理。资料提炼:共检索43篇关于神经干细胞增殖与分化分别与基因调控、生长因子、细胞因子及微环境信号等因素密切相关文章,31编符合纳入标准。排除的12篇试验中,8篇是因重复的同一研究,4篇是Meta分析研究。资料综合:神经干细胞是一种具有强大的自我更新能力和多向分化潜能的细胞,它具有分化为中枢神经系统内神经元、星形胶质细胞和少突胶质细胞的能力;其增殖与分化与基因调控、生长因子、细胞因子及微环境信号等因素密切相关,基本螺旋-环-螺旋基因、凋亡相关基因Bc1-XL、sox2等参与了神经干细胞的定向分化机制,notch信号通路、过氧化物酶体增殖分化激活受体Y信号通路也影响神经干细胞的分化方向。结论:神经干细胞的增殖与分化机制尚不十分清楚,其分化及调控机制是多因素调节和多因素相互作用的结果。 相似文献
70.
Arcese W; Goldman JM; D'Arcangelo E; Schattenberg A; Nardi A; Apperley JF; Frassoni F; Aversa F; Prentice HG; Ljungman P 《Blood》1993,82(10):3211-3219
We studied the clinical course of 130 chronic myeloid leukemia (CML) patients (89 males and 41 females) in the European Bone Marrow Transplantation Group (EBMT) registry who received transplants before January 1, 1988 and who subsequently had evidence of recurrent leukemia. All patients had received a pretransplant conditioning regimen including total body irradiation (TBI). The first evidence of relapse was cytogenetic only in 74 (57%) patients and hematologic in 56 (43%). The overall actuarial survival from relapse was 36% at 6 years, with a significantly higher proportion of survivors among female patients (53% v 30%; P < .002). In univariate analysis, the 6-year probability of survival was 52% for patients with cytogenetic relapse and 30% for patients relapsing in chronic phase (CP), while no patient who relapsed in advanced phase (AP or BC) survived more than 3.5 years from relapse (P < .0001). The actuarial survival of patients relapsing before 6 months, between 6 and 12 months, and later than 12 months after transplant was 27%, 26%, and 45%, respectively (P < .002). Among patients with cytogenetic relapse, partial or complete disappearance of Ph-positive cells occurred in 40% of untreated patients and in 42% of those treated with interferon (IFN). However, IFN therapy significantly delayed progression toward hematologic disease. Cytogenetic responses were observed in 25% of patients who received IFN for relapse into CP, while only one minor cytogenetic response was reported in patients on conventional chemotherapy. For patients presenting with cytogenetic relapse as well as for those in hematologic relapse, IFN therapy significantly improved the 2-year probability of survival. However, long-term survival for IFN-treated patients in either group was not different from long-term survival in comparable patients not receiving IFN therapy. Twenty-nine patients of this series underwent a second bone marrow transplant (BMT) and the projected survival at 4 years after the second transplant is 28%. In multivariate Cox regression analysis, four factors remained significantly associated with survival: disease phase at relapse (P < .0001), duration of time interval from BMT to relapse (P = .0001), interferon therapy at relapse (P = .0024), and patient sex (P = .0032). This retrospective study provides evidence that some patients who relapse after BMT may benefit from treatment with IFN; a second BMT may offer the chance of cure. Data from this analysis may be useful in designing future prospective trials on posttransplant CML relapse. 相似文献